Arena Submits NDA For Lorcaserin To FDA
Arena Pharmaceuticals (Arena) has submitted a New Drug Application (NDA) to the FDA for Lorcaserin, the company’s drug candidate for weight management, including weight loss and maintenance of
Rocket Pharmaceuticals has entered into a credit facility agreement of up to $150m with Hercules Capital to support the ongoing development of its cardiovascular portfolio.